Clinical trials: Resolution
Presbyopia
Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia
This is a Phase IIa study to assess efficacy and safety of STN1013600 ophthalmic solution (0.1%, and 0.3 %), twice daily when compared to Placebo in subjects diagnosed with presbyopia.
- Trial name
- OPSIS (NCT05665387)
- Testing
- 0.1% STN1013600 ophthalmic solution, 0.3% STN1013600 ophthalmic solution
- Where
- 12 sites in United States
- Volunteers
- 79 people
- Sponsor
- Santen Inc.
Anesthesia, Local
A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution
This is a Phase 3, randomized, placebo-controlled, double masked, parallel design study in healthy subjects performed in the US.
- Trial name
- NCT04513652
- Testing
- AG-920
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- American Genomics, LLC
Allergic Conjunctivitis
The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
- Trial name
- NCT04207736
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 95 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Pediatric Glaucoma, Elevated IOP in Pediatric Patients
Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of Travoprost 0.004% POLYQUAD (PQ) ophthalmic solution compared to Timolol ophthalmic solution (0.5% or 0.25%) in pediatric glaucoma…
- Conditions
- Pediatric Glaucoma, Elevated IOP in Pediatric Patients, Ocular Hypertension in Pediatric Patients
- Trial name
- NCT01652664
- Testing
- Travoprost 0.004% PQ ophthalmic solution, Timolol, 0.5% or 0.25% ophthalmic solution, Travoprost Vehicle
- Volunteers
- 184 people
- Sponsor
- Alcon Research
Open-angle Glaucoma, Ocular Hypertension
A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs
The objective of the study was to evaluate whether timolol hemihydrate is more comfortable upon instillation than timolol maleate in sorbate. This was an observational study.
- Trial name
- NCT00823043
- Testing
- timolol hemihydrate, timolol maleate
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Vistakon Pharmaceuticals
Left Ventricular Thrombosis
Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus
The purpose of this study is to compare the novel oral anticoagulant apixaban with the standard therapy of warfarin on the size reduction or resolution of left ventricular thrombus over 3 months.
- Trial name
- NCT02982590
- Testing
- Apixaban 5 MG Oral Tablet [ELIQUIS], Warfarin Sodium
- Where
- Malaysia
- Volunteers
- 27 people
- Sponsor
- Universiti Sains Malaysia
Chronic Obstructive Pulmonary Disease (COPD)
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
The primary objective of the study was to characterize the safety and tolerability of once-daily revefenacin inhalation solution when dosed sequentially with twice-daily formoterol inhalation solution (PERFOROMIST®) compared to…
- Trial name
- NCT03573817
- Testing
- Revefenacin, Formoterol
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Mylan Inc.
Corneal Epithelial Disorders
Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
The purpose of this study is to determine whether SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
- Trial name
- NCT02929823
- Testing
- High Dose SJP-0035 Ophthalmic Solution, Low Dose SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic solution
- Where
- 19 sites in United States
- Volunteers
- 130 people
- Sponsor
- Senju Pharmaceutical Co., Ltd.
Acute Pain
A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain
The purpose of the study was to evaluate the efficacy of tapentadol oral solution, based on the total amount of supplemental opioid analgesic used over 12 hours or 24 hours after initiation of investigational medicinal product…
- Trial name
- NCT02081391
- Testing
- Tapentadol oral solution 4 mg/mL, Tapentadol oral solution 20 mg/mL
- Where
- 43 sites in United States, Bulgaria and 8 more
- Volunteers
- 216 people
- Sponsor
- Grünenthal GmbH
Allergic Conjunctivitis
A Six-Week Safety Study of an Investigational Ophthalmic Solution
The purpose of this study was to evaluate the ocular safety of an investigational ophthalmic solution in subjects 2 years of age and older with asymptomatic eyes when administered once daily in both eyes for up to 6 weeks.
- Trial name
- NCT01698814
- Testing
- AL-4943A Ophthalmic Solution, AL-4943A Ophthalmic Solution Vehicle
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Dry Eye Disease
Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease
Primary Objectives: To compare the efficacy of cenegermin vs vehicle in Schirmer I test (without anaesthesia) > 10 mm/5 min at Week 4 by testing the superiority.
- Trial name
- PROTEGO-2 (NCT05136170)
- Testing
- Cenegermin, Vehicle
- Where
- 10 sites in United States, Italy
- Volunteers
- 85 people
- Sponsor
- Dompé Farmaceutici S.p.A
Breast Cancer, Early Detection of Cancer
A Prospective Study to Evaluate Clinical Performance of Thermalytix in Detecting Breast Cancers
The purpose of this study is to determine the clinical performance of AI-based Thermalytix with the current standard-of-care diagnostic modalities in women.
- Trial name
- NCT04688086
- Testing
- Thermalytix
- Where
- India
- Volunteers
- 687 people, healthy volunteers welcome
- Sponsor
- Niramai Health Analytix Private Limited
Chronic Obstructive Pulmonary Disease, Bronchitis
Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).
- Conditions
- Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
- Trial name
- NCT00250679
- Testing
- Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, Formoterol 12 ųg BID
- Where
- 60 sites in United States
- Volunteers
- 443 people
- Sponsor
- Sumitomo Pharma America, Inc.
Safety, Tolerability
Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+
Clinical phase I, controlled, non comparative, open, single center study evaluating the safety and tolerability of ophthalmic solution PRO-172 when applied on the ocular surface of healthy volunteers.
- Conditions
- Safety, Tolerability, Ocular Surface, Ocular Comfort
- Trial name
- PRO-172 (NCT04693429)
- Testing
- Bepotastine Besilate
- Where
- Mexico
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Atopic Dermatitis
A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
This is an open label, multicenter study designed to evaluate the safety and tolerability of ATI-502 Topical Solution in male and female subjects with moderate or severe atopic dermatitis (AD).
- Trial name
- NCT03585296
- Testing
- ATI-502
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Aclaris Therapeutics, Inc.
Onychomycosis
Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail
The purpose of the study is to determine the safety and efficacy of 5.0% AN2690 Solution in the treatment of distal, subungual onychomycosis of the great target toenail.
- Trial name
- NCT01278394
- Testing
- AN2690 Solution, 5.0%
- Where
- 2 sites in Mexico
- Volunteers
- 29 people
- Sponsor
- Pfizer
Dementia, Mental Health
Compass for Care: A Theory-driven Mobile Solution to Promote Well-being Among Caregivers of Individuals With ADRD
In the US, the over 11 million Americans currently providing unpaid care to a family member, relative, or friend with Alzheimer's disease or a related dementia (ADRD) are over 6 times more likely than the general population to…
- Trial name
- Compass4Care (NCT06249139)
- Testing
- Compass for Care (Well-being intervention), Compass for Care (Safety intervention)
- Where
- United States
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Pro-Change Behavior Systems
Allergic Conjunctivitis
Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis
The purpose of this study is to evaluate an ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.
- Trial name
- NCT01743027
- Testing
- AL-4943A ophthalmic solution, Olopatadine hydrochloride ophthalmic solution, 0.2%, Olopatadine hydrochloride ophthalmic solution, 0.1%
- Volunteers
- 902 people
- Sponsor
- Alcon Research
Dry Eye Syndrome
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects with Dry…
- Trial name
- NCT03404115
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.1%), Vehicle Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 300 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Pterygium
Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium
Stage 1: Single Ascending Dose, Safety, Tolerability and Pharmacokinetics (n=24) Stage 2: Multiple Dose, Safety and Efficacy Study with 28-day Dosing and 5 months Followup (n=51)
- Trial name
- Pterygium (NCT03049852)
- Testing
- CBT-001 single dose, Vehicle, CBT-001 Multi-dose
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Cloudbreak Therapeutics, LLC